Concurrent Expression of Cyclo-oxygenase-2 and Epidermal Growth Factor Receptor in Canine Malignant Mammary Tumours

Canine mammary tumours (CMTs) are reported to express cyclo-oxygenase (COX)-2 and epidermal growth factor receptor (EGFR); however, no studies have evaluated concurrent expression of these proteins. In this study, 43 malignant CMTs were evaluated immunohistochemically for concurrent expression of CO...

Full description

Saved in:
Bibliographic Details
Published in:Journal of comparative pathology 2014-01, Vol.150 (1), p.27-34
Main Authors: Guimarães, M.J., Carvalho, M.I., Pires, I., Prada, J., Gil, A. Gonzalez, Lopes, C., Queiroga, F.L.
Format: Article
Language:English
Subjects:
Animals
canine mammary tumours
Carcinoma - metabolism
Carcinoma - pathology
Carcinoma - veterinary
COX-2
Cyclooxygenase 2 - metabolism
Dog Diseases - metabolism
Dog Diseases - pathology
Dogs
EGFR
Female
Gene Expression Regulation, Neoplastic
Immunohistochemistry
Mammary Neoplasms, Animal - metabolism
Mammary Neoplasms, Animal - pathology
Receptor, Epidermal Growth Factor - metabolism
therapeutic target
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Canine mammary tumours (CMTs) are reported to express cyclo-oxygenase (COX)-2 and epidermal growth factor receptor (EGFR); however, no studies have evaluated concurrent expression of these proteins. In this study, 43 malignant CMTs were evaluated immunohistochemically for concurrent expression of COX-2 and EGFR and expression was correlated with malignancy. High COX-2 expression was associated with tumour size (P = 0.033), mitotic index (P = 0.040), nuclear grade (P = 0.021), histological grade of malignancy (P = 0.020) and lymph node metastasis (P = 0.029). High EGFR immunoreactivity was associated with tumour size (P = 0.001), necrosis (P = 0.001), mitotic index (P = 0.022), histological grade of malignancy (P = 0.041) and lymph node metastasis (P = 0.005). Simultaneous high-expression of COX-2 and EGFR was associated with high-nuclear grade (P = 0.049), high-histological grade of malignancy (P = 0.031) and the presence of lymph node metastasis (P = 0.025). A positive correlation between COX-2 and EGFR expression (r = 0.474; P = 0.001) was also observed. These results suggest that combined use of selective inhibitors of COX-2 and EGFR may be a useful approach to the treatment of malignant CMTs.
ISSN:0021-9975
1532-3129
DOI:10.1016/j.jcpa.2013.07.005